Citi opened a “high conviction 90-day Upside Catalyst Watch” on shares of Arcturus Therapeutics (ARCT). The firm keeps a Buy rating on the name with a $44 price target The company’s decision to rationalize spend and discontinue early-stage mRNA vaccine efforts with low return on investment visibility and “lower Street visibility” was smart, the analyst tells investors in a research note. Citi says Arcturus has two near-term pipeline catalysts mid-2025, and is trading marginally above cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
- Arcturus Therapeutics: Promising Vaccine Rollout and Cystic Fibrosis Treatment Drive Buy Rating
- Arcturus Therapeutics Reports Q1 2025 Financial Update
- Arcturus Therapeutics reports Q1 EPS (52c), consensus ($1.10)
- ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?